Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer
08 Mayo 2024 - 10:00AM
Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy
for Cancer, and Catalent Inc., the leader in enabling the
development and supply of better treatments for patients worldwide,
entered a strategic partnership to support the development and
manufacturing of Siren Biotechnology’s AAV immuno-gene therapies.
Under the partnership, Catalent will provide
process development and cGMP manufacturing of Siren Biotechnology’s
adeno-associated viral (AAV) vector-based therapeutic candidates
for use in clinical trials. Catalent will further support process
optimization at its process and clinical development center in
Baltimore, MD.
“We look forward to working with Catalent, a
leading CDMO with premier capabilities in AAV vector development
and manufacturing, on the development of our AAV Immuno-Gene
Therapies,” said Dr. Nicole Paulk, CEO, Founder, and President of
Siren Biotechnology. “This partnership demonstrates our commitment
to a robust manufacturing process that will move our therapeutic
programs into the clinic as quickly as possible. Catalent is the
only CDMO in the U.S. that has received FDA approval for AAV-based
gene therapies to date, and this was a significant factor in our
decision to partner with Catalent as we plan for future
commercialization of our upcoming clinical drug products.”
David McErlane, Group President of Biologics at
Catalent stated, “Catalent is committed to partnering early in the
development process with innovative companies like Siren. We are
excited to work together to pioneer a pathway for the development
and commercial manufacturing of safe, high-quality AAV gene
therapies to provide life-saving treatments to patients with
cancer.”
About Siren Biotechnology
Headquartered in San Francisco, CA, Siren Biotechnology is sounding
the alarm against cancer. We are the pioneers of Universal AAV
Immuno-Gene Therapy, which combines the promise of two
transformative therapeutic technologies, AAV gene therapy and
cytokine immunotherapy, into a single modality which we believe
will redefine how we destroy tumor cells and elicit anti-tumor
immunity. Our vision is for Universal AAV Immuno-Gene Therapy to
become the standard of care for any solid tumor cancer.
To learn more, visit sirenbiotechnology.com, and
follow us on LinkedIn and Twitter.Universal AAV Immuno-Gene Therapy
for Cancer. It’s Here.
Contact
Akela Kuwahara
press@sirenbiotechnology.com